Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada

Prevalence of Autism Spectrum Disorder (ASD) among children and youth aged 1 to 17 years, is about 2% (1 in 50) and is equivalent to about 150,000 cases in Canada in 2025 [1, 2]. Smith-Magenis syndrome (SMS) is a very rare (1:15,000 to 1:25,000 births) genetic neurodevelopmental disorder...